Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 145.26 USD -1.14% Market Closed
Market Cap: 14.5B USD

Intrinsic Value

The intrinsic value of one NBIX stock under the Base Case scenario is 150.55 USD. Compared to the current market price of 145.26 USD, Neurocrine Biosciences Inc is Undervalued by 4%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NBIX Intrinsic Value
150.55 USD
Undervaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Neurocrine Biosciences Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about NBIX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is NBIX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Neurocrine Biosciences Inc.

Explain Valuation
Compare NBIX to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Neurocrine Biosciences’ heavy reliance on Ingrezza for the bulk of its revenue leaves the company vulnerable should sales or market share of this core product decline, exposing a significant revenue concentration risk.

Patent expiration and looming generic entrants in the tardive dyskinesia space could erode Neurocrine’s pricing power, pressuring margins and diminishing its competitive edge.

Uncertainty around promising pipeline candidates, including potential delays or failures in late-stage clinical trials, could limit future growth opportunities and lead to increased R&D spend without near-term returns.

Bull Theses

Ingrezza continues to show strong sales momentum, fueled by expanding market penetration for tardive dyskinesia and steady physician adoption, supporting robust cash flows.

A well-funded R&D platform and a growing pipeline in movement disorders and other neurological conditions position Neurocrine for long-term growth if even a few candidates reach commercialization.

Partnerships with prominent pharmaceutical players, such as AbbVie, and recent collaborations for new programs help diversify Neurocrine’s development efforts, reduce risk, and expand its addressable markets.

Show More Less
How do you feel about NBIX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Neurocrine Biosciences Inc

Current Assets 2.2B
Cash & Short-Term Investments 1.1B
Receivables 728m
Other Current Assets 315.6m
Non-Current Assets 2.1B
Long-Term Investments 1.1B
PP&E 566.2m
Intangibles 35.7m
Other Non-Current Assets 388.8m
Current Liabilities 638m
Accounts Payable 396.8m
Accrued Liabilities 238.8m
Other Current Liabilities 2.4m
Non-Current Liabilities 624.1m
Other Non-Current Liabilities 624.1m
Efficiency

Free Cash Flow Analysis
Neurocrine Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Neurocrine Biosciences Inc

Revenue
2.7B USD
Cost of Revenue
-43.8m USD
Gross Profit
2.6B USD
Operating Expenses
-2.1B USD
Operating Income
553.6m USD
Other Expenses
-125.6m USD
Net Income
428m USD
Fundamental Scores

NBIX Profitability Score
Profitability Due Diligence

Neurocrine Biosciences Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Positive 3Y Average ROIC
Exceptional Gross Margin
Strong 3Y Average Gross Margin
ROE is Increasing
60/100
Profitability
Score

Neurocrine Biosciences Inc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

NBIX Solvency Score
Solvency Due Diligence

Neurocrine Biosciences Inc's solvency score is 90/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Short-Term Solvency
90/100
Solvency
Score

Neurocrine Biosciences Inc's solvency score is 90/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NBIX Price Targets Summary
Neurocrine Biosciences Inc

Wall Street analysts forecast NBIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NBIX is 181.85 USD with a low forecast of 148.47 USD and a high forecast of 213.15 USD.

Lowest
Price Target
148.47 USD
2% Upside
Average
Price Target
181.85 USD
25% Upside
Highest
Price Target
213.15 USD
47% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Neurocrine Biosciences Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for NBIX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

NBIX Insider Trading
Buy and sell transactions by insiders

NBIX News

Other Videos
What is the Intrinsic Value of one NBIX stock?

The intrinsic value of one NBIX stock under the Base Case scenario is 150.55 USD.

Is NBIX stock undervalued or overvalued?

Compared to the current market price of 145.26 USD, Neurocrine Biosciences Inc is Undervalued by 4%.

Back to Top